NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16628
Abstract: Myelodysplastic syndrome (MDS) consists of a heterogeneous group of clonal haematopoietic stem cell disorders that are characterized by peripheral cytopenia, hypercellular bone marrow (BM), and increased mortality due to the progression to acute myeloid leukaemia… read more here.
Keywords: dnmt3a; response; decitabine therapy; npm1 mutations ... See more keywords